These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39123485)

  • 1. Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression.
    Mondal V; Higgins PJ; Samarakoon R
    Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
    Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
    Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
    Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
    Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
    Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
    Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
    Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
    Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
    Juan WC; Hong W
    Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 12. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
    Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
    Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
    Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippo-Independent Regulation of Yki/Yap/Taz: A Non-canonical View.
    Cho YS; Jiang J
    Front Cell Dev Biol; 2021; 9():658481. PubMed ID: 33869224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the ambivalent role of YAP/TAZ in human cancers.
    Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
    J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.